InvestChile: Foreign Investment Rises 12% in 2022 in Chile,
According to InvestChile's analysis, this is 36% higher than the five-year average of US$12.617 billion and 23% higher
Globe Newswire11-02-2023, 13:19
Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00